143 related articles for article (PubMed ID: 34256093)
1. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
Yusenko MV; Biyanee A; Andersson MK; Radetzki S; von Kries JP; Stenman G; Klempnauer KH
Cancer Lett; 2021 Nov; 520():132-142. PubMed ID: 34256093
[TBL] [Abstract][Full Text] [Related]
2. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
[TBL] [Abstract][Full Text] [Related]
3. Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner.
Biyanee A; Yusenko MV; Klempnauer KH
Cells; 2022 Mar; 11(7):. PubMed ID: 35406726
[TBL] [Abstract][Full Text] [Related]
4. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
6. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
[TBL] [Abstract][Full Text] [Related]
7. MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.
Jiang Y; Gao R; Cao C; Forbes L; Li J; Freeberg S; Fredenburg KM; Justice JM; Silver NL; Wu L; Varma S; West R; Licht JD; Zajac-Kaye M; Kentsis A; Kaye FJ
Oral Oncol; 2019 Nov; 98():147-155. PubMed ID: 31606723
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells.
Uttarkar S; Piontek T; Dukare S; Schomburg C; Schlenke P; Berdel WE; Müller-Tidow C; Schmidt TJ; Klempnauer KH
Mol Cancer Ther; 2016 Dec; 15(12):2905-2915. PubMed ID: 27707899
[TBL] [Abstract][Full Text] [Related]
9. Zebrafish blastomere screen identifies retinoic acid suppression of
Mandelbaum J; Shestopalov IA; Henderson RE; Chau NG; Knoechel B; Wick MJ; Zon LI
J Exp Med; 2018 Oct; 215(10):2673-2685. PubMed ID: 30209067
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
[TBL] [Abstract][Full Text] [Related]
11. C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
Klempnauer KH
Exp Hematol; 2022 Apr; 108():8-15. PubMed ID: 35032593
[TBL] [Abstract][Full Text] [Related]
12. Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity.
Yusenko MV; Biyanee A; Frank D; Köhler LHF; Andersson MK; Khandanpour C; Schobert R; Stenman G; Biersack B; Klempnauer KH
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008207
[TBL] [Abstract][Full Text] [Related]
13. Peptidomimetic blockade of MYB in acute myeloid leukemia.
Ramaswamy K; Forbes L; Minuesa G; Gindin T; Brown F; Kharas MG; Krivtsov AV; Armstrong SA; Still E; de Stanchina E; Knoechel B; Koche R; Kentsis A
Nat Commun; 2018 Jan; 9(1):110. PubMed ID: 29317678
[TBL] [Abstract][Full Text] [Related]
14. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
Elife; 2021 Feb; 10():. PubMed ID: 33527899
[TBL] [Abstract][Full Text] [Related]
15. Transcription Factor MYB as Therapeutic Target: Current Developments.
Klempnauer KH
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542205
[TBL] [Abstract][Full Text] [Related]
16. Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300.
Uttarkar S; Dukare S; Bopp B; Goblirsch M; Jose J; Klempnauer KH
Mol Cancer Ther; 2015 Jun; 14(6):1276-85. PubMed ID: 25740244
[TBL] [Abstract][Full Text] [Related]
17. A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb.
Joy ST; Henley MJ; De Salle SN; Beyersdorf MS; Vock IW; Huldin AJL; Mapp AK
J Am Chem Soc; 2021 Sep; 143(37):15056-15062. PubMed ID: 34491719
[TBL] [Abstract][Full Text] [Related]
18. MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma.
Xu LH; Zhao F; Yang WW; Chen CW; Du ZH; Fu M; Ge XY; Li SL
Int J Oncol; 2019 May; 54(5):1579-1590. PubMed ID: 30896785
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of ZFAS1 suppresses the progression of acute myeloid leukemia by regulating microRNA-150/Sp1 and microRNA-150/Myb pathways.
Gan S; Ma P; Ma J; Wang W; Han H; Chen L; Li X; Wu F; Sun H
Eur J Pharmacol; 2019 Feb; 844():38-48. PubMed ID: 30502345
[TBL] [Abstract][Full Text] [Related]
20. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
